Energenesis Biomedical Co EV/FCF

Que fait Energenesis Biomedical Co ? Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue. Energenesis Biomedical Co est l'une des entreprises les plus populaires sur Eulerpool.